ABcann Global Announces Receipt of Health Canada License to Produce Cannabis Oils
02 January 2018 - 11:00PM
ABCANN GLOBAL CORPORATION (TSX-V:ABCN)
(“
ABcann” or the “
Company”) is
pleased to announce that the Company has been licensed by Health
Canada to produce medical cannabis oils. Once ABcann has saleable
extracted finished products, Health Canada will conduct a final
inspection to approve the sale of cannabis oils by the Company.
This is expected in the first quarter of 2018.
“Receipt of the license to produce cannabis oils
is a major milestone in our pursuit to provide our medical cannabis
patients with additional product formats that can be precisely
dosed,” commented Barry Fishman, CEO of ABcann. “The expansion and
innovation of our product lines are a top priority for the Company
as we continue to serve the needs of our customers, and we
anticipate strong demand for our cannabis oil products.”
About ABcann:
ABcann holds production and sales licenses from
Health Canada. Its flagship facility in Napanee, Ontario contains
proprietary plant-growing technology, centred on its specially
designed, environmentally-controlled growing chambers. This
approach results in the production of pharmaceutical-grade cannabis
products.
The Company is expanding its cultivation
capacity and pursuing partnership and product development
opportunities domestically, as well as in select international
markets, such as Germany, Australia and Israel.
ON BEHALF OF THE BOARD OF DIRECTORS
"Barry Fishman"
Barry Fishman CEO and Director
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Disclaimer for Forward-Looking Information
Certain statements in this news release are
forward-looking statements, which are statements that are not
purely historical, regarding the beliefs, plans, expectations or
intentions of ABcann and its management regarding the future.
Forward looking statements in this news release include statements
relating to the Company’s potential new products and product line
innovations, timing of approval from Health Canada for the sale of
cannabis oils, expected demand for cannabis oil products, and
ABcann’s future plans with respect to cultivation, distribution and
imports into Germany, Australia and other international
jurisdictions. Such statements are subject to risks and
uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
forward-looking statements, including potential delays in
formulating new product lines or producing saleable extracted
finished products, potential delays in the timing of Health Canada
approval for the sale of cannabis oils and other factors beyond the
Company’s control. No assurance can be given that any of the events
anticipated by the forward-looking statements will occur or, if
they do occur, what benefits the Company will obtain from them.
Readers are urged to consider these factors, and the more extensive
risk factors included in the Company’s filing statement dated March
31, 2017, which is available on SEDAR, carefully in evaluating the
forward-looking statements, and are cautioned not to place undue
reliance on such forward-looking statements, which are qualified in
their entirety by these cautionary statements. The forward-looking
statements in this news release are made as of the date hereof and
the Company disclaims any intent or obligation to update publicly
any such forward-looking statements, whether as a result of new
information, future events or results or otherwise, except as
required by applicable securities laws.
For further information, please contact:
• Barry Fishman (CEO and Director) at barry.fishman@abcannglobal.com
• Aaron Keay (Director) at aaron@abcannglobal.com or
• Michael Bumby (CFO) at michael.bumby@abcannglobal.com
Abcann Global Corporation (TSXV:ABCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Abcann Global Corporation (TSXV:ABCN)
Historical Stock Chart
From Jul 2023 to Jul 2024